Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of genomic science expert Sequenom
So what: Last night's second-quarter report was somewhat disappointing, missing the Street's earnings targets by 23% despite cutting losses dramatically year over year. Management said that the quarter met internal goals of "continued revenue growth and effective cost controls," but that wasn't good enough for grumpy investors.
Now what: One shudders to think what might have happened to Sequenom if analysts were critical of the results! Two firms reiterated their existing stances of one buy and one hold. By contrast, sector rival Pacific Biosciences of California
Interested in more info on Sequenom? Add it to your watchlist.